As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Sarepta Therapeutics, Inc. The largest reported stake is BlackRock, Inc.'s, at 15.8%. 15 filings are on record since July 25, 2025 (Schedule 13G/A, July 30, 2026).
Sell to companies like Sarepta Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: AQR Capital Management, LLC · Sole voting: 0 · Shared voting: 4,916,753 · Sole dispositive: 0 · Shared dispositive: 5,329,691 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 8,642,126 · Sole dispositive: 0 · Shared dispositive: 8,916,103 · SCHEDULE 13G, 2026-08-07
- · Reporting person: Vanguard Portfolio Management · Sole voting: 121,951 · Shared voting: 0 · Sole dispositive: 8,499,421 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-31
- · Reporting person: BlackRock, Inc. · Sole voting: 16,353,161 · Shared voting: 0 · Sole dispositive: 16,642,620 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-30
- · Holder: Vanguard Capital Management · Percent: 5.11% · SCHEDULE 13G
Sarepta Therapeutics, Inc. has 15 Schedule 13D or 13G filings on record since 2025-07-25. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 15.8% | 16,642,620 | SCHEDULE 13G/A, 2026-07-30 | 2026-06-30 |
| State Street Corporation | 8.4% | 8,916,103 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Vanguard Portfolio Management | 8.05% | 8,499,421 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
| Vanguard Capital Management | 5.11% | 5,369,116 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| AQR Capital Management, LLC | 5.05% | 5,329,691 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| D. E. Shaw & Co., L.P. | 1.9% | 2,007,025 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Capital International Investors | 0.5% | 524,146 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Sarepta Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Sarepta Therapeutics, Inc. and the records around it.
Sarepta Therapeutics, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- D. E. Shaw & Co., L.P. also filed stake reports on 28 other companies: Gossamer Bio, Inc. (Oct 2026), Sweetgreen, Inc. (Oct 2026), Venture Global, Inc. (Sep 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Watch Sarepta Therapeutics, Inc.
Get an email when Sarepta Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sarepta Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sarepta Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sarepta Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 16,353,161 | 0 | 16,642,620 | 0 | SCHEDULE 13G/A, 2026-07-30 |
| State Street Corporation | 0 | 8,642,126 | 0 | 8,916,103 | SCHEDULE 13G, 2026-08-07 |
| Ssga Funds Management, Inc. | 0 | 6,271,147 | 0 | 6,285,547 | SCHEDULE 13G, 2026-08-07 |
| Vanguard Portfolio Management | 121,951 | 0 | 8,499,421 | 0 | SCHEDULE 13G/A, 2026-07-31 |
| AQR Capital Management, LLC | 0 | 4,916,753 | 0 | 5,329,691 | SCHEDULE 13G/A, 2026-08-13 |
| AQR Capital Management Holdings, LLC | 0 | 4,916,753 | 0 | 5,329,691 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Sarepta Therapeutics, Inc. by CUSIP 803607100 and gives its principal executive office as 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA 02142 (SCHEDULE 13G/A, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-25 | D. E. Shaw & Co., L.P. | 5.1% | SCHEDULE 13G |
| 2025-07-25 | D. E. Shaw & Co., L.P. | 5.1% | SCHEDULE 13G/A |
| 2025-08-13 | Capital International Investors | 0.5% | SCHEDULE 13G/A |
| 2025-09-08 | The Vanguard Group | 10.89% | SCHEDULE 13G/A |
| 2025-11-10 | State Street Corporation | 5.4% | SCHEDULE 13G |
| 2025-11-14 | D. E. Shaw & Co., L.P. | 1.9% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 12.6% | SCHEDULE 13G/A |
| 2026-02-13 | AQR Capital Management, LLC | 7.73% | SCHEDULE 13G |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Portfolio Management | 6.43% | SCHEDULE 13G |
| 2026-04-30 | Vanguard Capital Management | 5.11% | SCHEDULE 13G |
| 2026-07-30 | BlackRock, Inc. | 15.8% | SCHEDULE 13G/A |
| 2026-07-31 | Vanguard Portfolio Management | 8.05% | SCHEDULE 13G/A |
| 2026-08-07 | State Street Corporation | 8.4% | SCHEDULE 13G |
| 2026-08-13 | AQR Capital Management, LLC | 5.05% | SCHEDULE 13G/A |
Questions about who owns Sarepta Therapeutics, Inc.
Who owns Sarepta Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Sarepta Therapeutics, Inc.: BlackRock, Inc. (15.8%, Schedule 13G/A, filed 2026-07-30), State Street Corporation (8.4%, Schedule 13G, filed 2026-08-07), Vanguard Portfolio Management (8.05%, Schedule 13G/A, filed 2026-07-31), Vanguard Capital Management (5.11%, Schedule 13G, filed 2026-04-30) and AQR Capital Management, LLC (5.05%, Schedule 13G/A, filed 2026-08-13).
Who are the largest shareholders of Sarepta Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Sarepta Therapeutics, Inc. on this page are BlackRock, Inc. (15.8%), State Street Corporation (8.4%) and Vanguard Portfolio Management (8.05%).
When did BlackRock, Inc. buy into Sarepta Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2026-01-21, reporting 12.6%; its latest, Schedule 13G/A filed 2026-07-30, reports 15.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Sarepta Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Leadership change: Michael Severino appointed, Chief Executive Officer, and 2 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Sarepta Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.